# Thar Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/thar-pharmaceuticals

- Industry: Pharmaceuticals
- Headquarters: Pittsburgh, US
- Website: www.tharpharma.com
- Total disclosed funding: $0.3M
- Latest round: Series A (Oct 26, 2011)
- Investors on record: 1

## About

Thar Pharmaceuticals, Inc. specializes in pharmaceutical development, focusing primarily on the innovation and commercialization of therapeutic products.Founded in 2008 in Pittsburgh, US, Thar Pharmaceuticals, Inc. engages in pharmaceutical development, particularly in specialized therapeutic products. The company was acquired by Grünenthal Group in November 2016 for an undisclosed amount. Since its inception, Thar has completed a total of 10 deals, with its most recent deal occurring on November 16, 2016. Thar Pharmaceuticals has raised a total of USD 0.33 mn, with the latest funding round being a Venture Debt amounting to USD 1.37 mn.Thar Pharmaceuticals focuses on the research and development of innovative therapeutic products, employing advanced pharmaceutical technologies. Their offerings are designed to address unmet medical needs, providing healthcare solutions with a focus on efficacy and safety. The company collaborates with various stakeholders, including healthcare providers and research institutions, to enhance product development and delivery.The revenue model of Thar Pharmaceuticals is based on strategic partnerships and collaborations in the pharmaceutical sector, providing access to their proprietary technologies and therapeutic developments. The financial details regarding individual product revenues are not disclosed, but the company aims to generate revenue through successful commercialization of their products and partnerships with other firms in the industry.Thar Pharmaceuticals plans to expand its product offerings, focusing on new therapeutic developments that address specific health challenges, with launches anticipated in the coming years. The company is also targeting expansion into international markets, particularly in Europe and Asia, by 2025 to increase its global reach. Recent funding from the acquisition will be utilized to enhance research capabilities and support the development of new products and technologies.

## Funding rounds

- Series A, Oct 26, 2011, $0.3M — Channel Capital

## Investors

- Channel Capital (https://capitalatlas.ai/funds/channel-capital) — Series A